secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVAI BIO, INC. (AVAI)
CIK:        0001740797
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001740797-25-000030
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avant Technologies terminates ELOC with GHS Investments, plans new equity line with $2 floor price
--------------------------------------------------------------------------------

- Effective May 13, 2025, the company and GHS Investments mutually terminated the July 17, 2024 Equity Financing Agreement (ELOC).
- Termination was based on evaluation that existing terms, including the minimum floor price, no longer aligned with business strategy.
- Company will withdraw its pending Form S-1 and pursue a new ELOC with a higher minimum floor price of $2.00 per share.
- Both parties confirmed no further obligations or liabilities under the terminated agreements.
- New ELOC structure is intended to improve terms, compliance, and shareholder alignment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740797/000174079725000030/0001740797-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740797/000174079725000030/avai_8kmay132025.htm
  HTML page:      https://secwatch.observer/filing/0001740797-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer